Australian Clinical Labs (ASX:ACL) share price falls despite tripling profits and beating guidance

This healthcare share had a strong half..

| More on:
A man wearing a white coat and glasses is wide-mouthed in surprise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Australian Clinical Labs was in fine form during the first half
  • The pathology company tripled its profits and beat its upgraded guidance
  • Strong demand for COVID testing services helped drive its growth

The Australian Clinical Labs Ltd (ASX: ACL) share price dropped with the market on Thursday despite the release of a strong half year update from the pathology company.

The company's shares ended the day 3.5% lower at $4.85.

Australian Clinical Labs share price lower despite strong growth

  • Total revenue up 61.2% to $538 million
  • EBITDA up 112.1% to $239.3 million
  • Net profit after tax up 200% to $130.3 million
  • Fully franked interim dividend of 12 cents per share

What happened during the first half?

For the six months ended 31 December, Australian Clinical Labs delivered a 61.2% increase in revenue to $538 million. This strong growth was driven by significant demand for COVID testing and a rapid and substantial increase in capacity to capture it.

This was also supported by modest growth from its non-COVID operations, which reported a 2.8% increase in revenue over the prior corresponding period.

Thanks to significant operating leverage, the company's EBIT margin increased from 20.5% to 35.5%, which ultimately underpinned a net profit after tax of $130.3 million. This was triple what it achieved a year earlier and ahead of its upgraded guidance of $116.3 million to $128 million. It was also 4% ahead of consensus estimates.

Management commentary

Australian Clinical Labs' Chief Executive Officer and Executive Director, Melinda McGrath, was pleased with the company's performance in a challenging operating environment..

She said: "During the past two years, Clinical Labs has played an essential role in Australia's response to COVID during what was at times a challenging operating environment. At the same time the team have delivered growth in our core business, driven operational improvements across the organisation while simultaneously completing two acquisitions. These achievements are a testament to the commitment and resilience of the ACL team."

"The strong result achieved in 1H FY22 demonstrates the value of the significant prior investment in the business which resulted in further operating leverage, efficiencies, improved productivity and increased automation and digitisation. There exist several opportunities to continue to grow the business including via our commercial offering and our established clinical trials business. We have strong foundations in technology and systems and a highly experienced performance-driven management team to execute our well-defined growth strategy."


Due to high levels of uncertainty, no guidance has been given for the remainder of FY 2022.

However, management has provided an idea on what it expects to occur in respect to testing volumes during the second half.

It explained: "During the 2H FY22, ACL anticipates testing for COVID to continue to moderate as the response to COVID transitions to an endemic virus. The pace with which COVID testing moderates will depend on several factors including future outbreaks, new variants, vaccination take up and effectiveness and government policy relating to lockdowns and travel."

"Assuming no significant outbreaks, ACL anticipates the rebound in non-COVID testing to continue as restrictions on essential surgeries ease and hospitals return to full capacity," it concluded.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Earnings Results

ASX 200 stock jumps 10% on strong FY24 results

How did this KFC restaurant operator perform in FY 2024?

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Consumer Staples & Discretionary Shares

Guess which ASX 200 stock just slashed its final dividend by 23%

This retailer had a tough time during the 12 months. Here's how it performed.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Earnings Results

Catapult shines: 20% sales growth propels ASX tech stock to new 52-week high

A strong annual result from this tech player has caught investor attention.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Earnings Results

Xero share price leaps 8% on staggering earnings upheaval

A major turnaround in profitability is sending investors into a frenzy over Xero shares today.

Read more »

a construction worker sits pensively at his desk with his arm propping up his chin as he looks at his laptop computer while wearing a hard hat and visibility vest in a bunker style construction shed.
Materials Shares

Which ASX 200 stock just plunged 12% despite record full-year earnings?

It looks like an impressive report card but UBS doesn't like the FY25 guidance.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

ASX 200 tech stock lifts off on another record-setting half-year profit

Investors are bidding up the ASX 200 tech company following its half-year results.

Read more »

increasing rural asx share price represented by happy looking sheep
Earnings Results

Why is this ASX All Ords stock staying strong as profits crash 76%

How is this company's share price marching higher after mowing down more than three-quarters of its profits compared to a…

Read more »

Two men sit side by side on a couch with video game controls in their hands and expressive looks on their faces as they react to the action in front of them in a home setting.
Earnings Results

Guess which ASX 200 stock is surging 11% on an 'outstanding' result

This ASX gaming giant just posted a 17% jump in profits, and its shareholders are basking in the glory.

Read more »